Search Results

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that an 1 for 5 reverse split of its authorized share capital, was approved by the Company’s board of directors on May 29, 2023 and will become effective on June 21, 2024.

China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.

On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China.

On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).

Gyre Therapeutics today announced that the Center for Drug Evaluation (“CDE”) of China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) Investigational New Drug (“IND”) application for F230 tablets.

One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.

Life Molecular Imaging and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® has received regulatory approval from National Medical Products Administration in China.

Aptorum Group Limited announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments.